Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Oxaliplatin"" wg kryterium: Temat


Tytuł :
Prevention of oxaliplatin-related neurotoxicity by ω-3 PUFAs: A double-blind randomized study of patients receiving oxaliplatin combined with capecitabine for colon cancer.
Autorzy :
Zhang X; Zhejiang Chinese Medical University.
Chen H; Zhejiang Chinese Medical University.
Lu Y; Department of Nutrition.
Xu C; Department of Integrated Traditional Chinese and Western Medicine, the Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital).
Yao W; Zhejiang Chinese Medical University.
Xu L; Zhejiang Chinese Medical University.
Zhang R; Zhejiang Chinese Medical University.
Zhang L; The First Affiliated Hospital of Zhejiang Chinese Medical University.
Yao Q; Department of Integrated Traditional Chinese and Western Medicine, the Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital).; Key Laboratory of Traditional Chinese Medicine Oncology, the Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 Dec 11; Vol. 99 (50), pp. e23564.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Capecitabine/*therapeutic use
Colonic Neoplasms/*drug therapy
Fatty Acids, Omega-3/*therapeutic use
Neuroprotective Agents/*therapeutic use
Neurotoxicity Syndromes/*prevention & control
Oxaliplatin/*toxicity
Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/toxicity ; Capecitabine/administration & dosage ; Double-Blind Method ; Drug Administration Schedule ; Fatty Acids, Omega-3/administration & dosage ; Female ; Humans ; Male ; Middle Aged ; Neuroprotective Agents/administration & dosage ; Neurotoxicity Syndromes/etiology ; Oxaliplatin/administration & dosage ; Oxaliplatin/therapeutic use ; Peripheral Nervous System Diseases/chemically induced ; Peripheral Nervous System Diseases/prevention & control ; Quality of Life ; Surveys and Questionnaires
Czasopismo naukowe
Tytuł :
Oxaliplatin-induced increase in splenic volume: experiences from multicenter study in Japan.
Autorzy :
Ohta R; Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8602, Japan.
Yamada T; Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8602, Japan. .
Hara K; Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8602, Japan.
Iwai T; Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8602, Japan.
Tanakaya K; Department of Surgery, National Hospital Organization Iwakuni Clinical Center, Iwakuni, Japan.
Ishibashi K; Department of Surgery Saitama Medical center, Saitama Medical University, Saitama, Japan.
Yoshimatsu K; Department of Surgery, Tokyo Women's Medical University, Medical Center East, Tokyo, Japan.
Kosugi C; Department of Surgery, Teikyo University Chiba Medical Center, Chiba, Japan.
Tsubaki M; Department of Surgery, Yuai Memorial Hospital, Koga, Japan.
Nakajima H; Department of Oncology, Ageo Central General Hospital, Ageo, Japan.
Oya M; Department of Surgery Saitama Medical center, Dokkyo University School of Medicine, Mibu, Japan.
Yoshida H; Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8602, Japan.
Koda K; Department of Surgery, Teikyo University Chiba Medical Center, Chiba, Japan.
Ishida H; Department of Surgery Saitama Medical center, Saitama Medical University, Saitama, Japan.
Pokaż więcej
Źródło :
International journal of clinical oncology [Int J Clin Oncol] 2020 Dec; Vol. 25 (12), pp. 2075-2082. Date of Electronic Publication: 2020 Aug 12.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Colonic Neoplasms/*drug therapy
Oxaliplatin/*adverse effects
Splenic Diseases/*chemically induced
Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chemotherapy, Adjuvant/adverse effects ; Colonic Neoplasms/mortality ; Colonic Neoplasms/pathology ; Disease-Free Survival ; Female ; Fluorouracil/adverse effects ; Fluorouracil/therapeutic use ; Humans ; Japan ; Leucovorin/adverse effects ; Leucovorin/therapeutic use ; Male ; Middle Aged ; Organoplatinum Compounds/adverse effects ; Organoplatinum Compounds/therapeutic use ; Oxaliplatin/administration & dosage ; Prognosis ; Splenic Diseases/diagnostic imaging
SCR Protocol :
Folfox protocol
Czasopismo naukowe
Tytuł :
Acute chemotherapy-induced peripheral neuropathy due to oxaliplatin administration without cold stimulation.
Autorzy :
Matsumoto Y; Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Nanakuma 7-45-1, Jonan-ku, Fukuoka, 814-0180, Japan.
Yoshida Y; Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Nanakuma 7-45-1, Jonan-ku, Fukuoka, 814-0180, Japan. .
Kiba S; Nursing Department, Fukuoka University Hospital, Nanakuma 7-45-1, Jonan-ku, Fukuoka, 814-0180, Japan.
Yamashiro S; Nursing Department, Fukuoka University Hospital, Nanakuma 7-45-1, Jonan-ku, Fukuoka, 814-0180, Japan.
Nogami H; Nursing Department, Fukuoka University Hospital, Nanakuma 7-45-1, Jonan-ku, Fukuoka, 814-0180, Japan.
Ohashi N; Nursing Department, Fukuoka University Hospital, Nanakuma 7-45-1, Jonan-ku, Fukuoka, 814-0180, Japan.
Kajitani R; Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Nanakuma 7-45-1, Jonan-ku, Fukuoka, 814-0180, Japan.
Munechika T; Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Nanakuma 7-45-1, Jonan-ku, Fukuoka, 814-0180, Japan.
Nagano H; Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Nanakuma 7-45-1, Jonan-ku, Fukuoka, 814-0180, Japan.
Komono A; Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Nanakuma 7-45-1, Jonan-ku, Fukuoka, 814-0180, Japan.
Aisu N; Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Nanakuma 7-45-1, Jonan-ku, Fukuoka, 814-0180, Japan.
Yoshimatsu G; Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Nanakuma 7-45-1, Jonan-ku, Fukuoka, 814-0180, Japan.
Hasegawa S; Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Nanakuma 7-45-1, Jonan-ku, Fukuoka, 814-0180, Japan.
Pokaż więcej
Źródło :
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2020 Nov; Vol. 28 (11), pp. 5405-5410. Date of Electronic Publication: 2020 Mar 06.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Oxaliplatin/*adverse effects
Peripheral Nervous System Diseases/*chemically induced
Peripheral Nervous System Diseases/*epidemiology
Acute Disease ; Adult ; Aged ; Aged, 80 and over ; Cold Temperature/adverse effects ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/epidemiology ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Oxaliplatin/administration & dosage ; Paresthesia/chemically induced ; Paresthesia/epidemiology ; Physical Stimulation/adverse effects ; Prevalence ; Time Factors
Czasopismo naukowe
Tytuł :
GOLPH3 inhibition reverses oxaliplatin resistance of colon cancer cells via suppression of PI3K/AKT/mTOR pathway.
Autorzy :
Yu T; Department of General Surgery, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, PR China.
An Q; Department of General Surgery, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, PR China.
Cao XL; Department of General Surgery, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, PR China.
Yang H; Department of General Surgery, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, PR China.
Cui J; Department of General Surgery, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, PR China.
Li ZJ; Department of General Surgery, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, PR China.
Xiao G; Department of General Surgery, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, PR China. Electronic address: .
Pokaż więcej
Źródło :
Life sciences [Life Sci] 2020 Nov 01; Vol. 260, pp. 118294. Date of Electronic Publication: 2020 Aug 18.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Resistance, Neoplasm/*physiology
Membrane Proteins/*physiology
Oxaliplatin/*therapeutic use
Phosphatidylinositol 3-Kinases/*metabolism
Proto-Oncogene Proteins c-akt/*metabolism
TOR Serine-Threonine Kinases/*metabolism
Animals ; Apoptosis/drug effects ; Cell Cycle/drug effects ; Colonic Neoplasms/drug therapy ; Colonic Neoplasms/pathology ; Drug Resistance, Neoplasm/drug effects ; HCT116 Cells ; Humans ; Imidazoles/pharmacology ; Male ; Membrane Proteins/antagonists & inhibitors ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Oxaliplatin/pharmacology ; Quinolines/pharmacology ; RNA, Small Interfering/pharmacology ; Signal Transduction/drug effects ; Signal Transduction/physiology
Czasopismo naukowe
Tytuł :
A new monitoring tool CLIP test for progression of oxaliplatin-induced peripheral neuropathy: A multicenter prospective study.
Autorzy :
Kamei K; Department of Surgery, Kindai University Faculty of Medicine, Osakasayama, Japan.
Ohnishi T; Department of Surgery, Nishinomiya Municipal Central Hospital, Nishinomiya, Japan.
Nakata K; Department of Coloproctological Surgery, Sakai City Medical Center, Sakai, Japan.
Danno K; Department of Surgery, Minoh City Hospital, Minoh, Japan.
Ohkawa A; Department of Surgery, Higashi Takarazuka Satoh Hospital, Takarazuka, Japan.
Miyake Y; Department of Surgery, Osaka Minato Central Hospital, Osaka, Japan.
Okazaki S; Department of Surgery, Kansai Medical University Kori Hospital, Neyagawa, Japan.
Fukunaga M; Department of Surgery, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan.
Toyokawa A; Department of Surgery, Akashi Medical Center, Akashi, Japan.
Hamada T; Department of Surgery, Takarazuka City Hospital, Takarazuka, Japan.
Shindoh J; Department of Gastroenterological Surgery, Toranomon Hospital, Tokyo, Japan.
Kanazawa A; Department of Surgery, Shimane Prefectural Central Hospital, Izumo, Japan.
Pokaż więcej
Źródło :
Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2020 Oct; Vol. 16 (5), pp. e257-e262. Date of Electronic Publication: 2020 Sep 07.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Oxaliplatin/*adverse effects
Peripheral Nervous System Diseases/*chemically induced
Quality of Life/*psychology
Adult ; Aged ; Antineoplastic Agents/therapeutic use ; Disease Progression ; Female ; Humans ; Male ; Middle Aged ; Oxaliplatin/pharmacology ; Prospective Studies
Czasopismo naukowe
Tytuł :
Predictive clinical factors of chronic peripheral neuropathy induced by oxaliplatin.
Autorzy :
Yildirim N; Department of Medical Oncology, Firat University School of Medicine, Elazıg, Turkey. .
Cengiz M; Department of Internal Medicine, Biruni University School of Medicine, İstanbul, Turkey.
Pokaż więcej
Źródło :
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2020 Oct; Vol. 28 (10), pp. 4781-4788. Date of Electronic Publication: 2020 Jan 23.
Typ publikacji :
Journal Article
MeSH Terms :
Oxaliplatin/*adverse effects
Peripheral Nervous System Diseases/*chemically induced
Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Capecitabine/administration & dosage ; Capecitabine/adverse effects ; Colorectal Neoplasms/blood ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/pathology ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Humans ; Incidence ; Leucovorin/administration & dosage ; Leucovorin/adverse effects ; Logistic Models ; Male ; Middle Aged ; Organoplatinum Compounds/administration & dosage ; Organoplatinum Compounds/adverse effects ; Oxaliplatin/administration & dosage ; Oxaloacetates/administration & dosage ; Oxaloacetates/adverse effects ; Peripheral Nervous System Diseases/blood ; Peripheral Nervous System Diseases/pathology ; Retrospective Studies ; Vitamin D/blood
SCR Protocol :
Folfox protocol; XELOX
Czasopismo naukowe
Tytuł :
Protective effect of N-acetylcysteine on oxaliplatin-induced neurotoxicity in patients with colorectal and gastric cancers: A randomized, double blind, placebo-controlled, clinical trial.
Autorzy :
Bondad N; Department of Internal Medicine, Mashhad University of Medical sciences, Mashhad, Iran.
Boostani R; Department of Neurology, Mashhad University of Medical Sciences, Mashhad, Iran.
Barri A; Department of Hematology and Medical Oncology, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Elyasi S; Department of Clinical Pharmacy, Faculty of Pharmacy, University of Medical Sciences, Mashhad, Iran.
Allahyari A; Department of Hematology and Medical Oncology, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Pokaż więcej
Źródło :
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2020 Oct; Vol. 26 (7), pp. 1575-1582. Date of Electronic Publication: 2020 Feb 17.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Acetylcysteine/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Capecitabine/*adverse effects
Neurotoxicity Syndromes/*prevention & control
Oxaliplatin/*adverse effects
Oxaloacetates/*adverse effects
Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Capecitabine/administration & dosage ; Colorectal Neoplasms/drug therapy ; Double-Blind Method ; Female ; Humans ; Male ; Middle Aged ; Neurotoxicity Syndromes/etiology ; Oxaliplatin/administration & dosage ; Oxaloacetates/administration & dosage ; Stomach Neoplasms/drug therapy
SCR Protocol :
XELOX
Czasopismo naukowe
Tytuł :
Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases.
Autorzy :
Boilève A; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France. Electronic address: .
De Cuyper A; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France; Department of Medical Oncology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Larive A; Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France.
Mahjoubi L; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
Najdawi M; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
Tazdait M; Department of Radiology, Gustave Roussy Cancer Campus, Villejuif, France.
Gelli M; Department of Surgery, Gustave Roussy Cancer Campus, Villejuif, France.
Tselikas L; Department of Interventional Radiology, Gustave Roussy Cancer Campus, Villejuif, France.
Smolenschi C; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
Malka D; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
Pignon JP; Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France; Oncostat U1018, Inserm, University Paris-Saclay, Labeled Ligue Contre le Cancer, Villejuif, France.
Ducreux M; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France; Paris-Saclay University, Villejuif, France.
Boige V; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
Pokaż więcej
Źródło :
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2020 Oct; Vol. 138, pp. 89-98. Date of Electronic Publication: 2020 Aug 29.
Typ publikacji :
Journal Article
MeSH Terms :
Colorectal Neoplasms/*pathology
Liver Neoplasms/*drug therapy
Liver Neoplasms/*secondary
Oxaliplatin/*administration & dosage
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Bevacizumab/administration & dosage ; Camptothecin/administration & dosage ; Camptothecin/analogs & derivatives ; ErbB Receptors/antagonists & inhibitors ; Female ; Fluorouracil/administration & dosage ; Hepatic Artery ; Humans ; Infusions, Intra-Arterial ; Leucovorin/administration & dosage ; Liver Neoplasms/mortality ; Male ; Middle Aged ; Oxaliplatin/adverse effects
SCR Protocol :
IFL protocol
Czasopismo naukowe
Tytuł :
Protective effect of the oral administration of cystine and theanine on oxaliplatin-induced peripheral neuropathy: a pilot randomized trial.
Autorzy :
Kobayashi M; Department of Surgery, Sendai City Medical Center, 5-22-1 Tsurugaya, Miyagino-ku, Sendai, Miyagi, 983-0824, Japan.; Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Sato R; Department of Surgery, Sendai City Medical Center, 5-22-1 Tsurugaya, Miyagino-ku, Sendai, Miyagi, 983-0824, Japan.
Komura T; Department of Surgery, Omagari Kousei Medical Center, Akita, Akita, Japan.
Ichikawa H; Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Hirashima T; Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Otake S; Department of Surgery, Sendai City Medical Center, 5-22-1 Tsurugaya, Miyagino-ku, Sendai, Miyagi, 983-0824, Japan.
Akazawa N; Department of Surgery, Sendai City Medical Center, 5-22-1 Tsurugaya, Miyagino-ku, Sendai, Miyagi, 983-0824, Japan.
Yazawa T; Department of Surgery, Sendai City Medical Center, 5-22-1 Tsurugaya, Miyagino-ku, Sendai, Miyagi, 983-0824, Japan.
Abe T; Department of Surgery, Sendai City Medical Center, 5-22-1 Tsurugaya, Miyagino-ku, Sendai, Miyagi, 983-0824, Japan.
Okada T; Department of Surgery, Sendai City Medical Center, 5-22-1 Tsurugaya, Miyagino-ku, Sendai, Miyagi, 983-0824, Japan.
Kakita T; Department of Surgery, Sendai City Medical Center, 5-22-1 Tsurugaya, Miyagino-ku, Sendai, Miyagi, 983-0824, Japan.
Oikawa M; Department of Surgery, Sendai City Medical Center, 5-22-1 Tsurugaya, Miyagino-ku, Sendai, Miyagi, 983-0824, Japan.
Tsuchiya T; Department of Surgery, Sendai City Medical Center, 5-22-1 Tsurugaya, Miyagino-ku, Sendai, Miyagi, 983-0824, Japan. .
Pokaż więcej
Źródło :
International journal of clinical oncology [Int J Clin Oncol] 2020 Oct; Vol. 25 (10), pp. 1814-1821. Date of Electronic Publication: 2020 Jun 27.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Colorectal Neoplasms/*drug therapy
Glutamates/*administration & dosage
Oxaliplatin/*adverse effects
Peripheral Nervous System Diseases/*chemically induced
Peripheral Nervous System Diseases/*prevention & control
Administration, Oral ; Aged ; Cystine/administration & dosage ; Female ; Fluorouracil/adverse effects ; Humans ; Leucovorin/adverse effects ; Male ; Middle Aged ; Organoplatinum Compounds/adverse effects ; Oxaliplatin/administration & dosage ; Pilot Projects ; Quality of Life
SCR Protocol :
Folfox protocol
Czasopismo naukowe
Tytuł :
Long-Circulating Thermosensitive Liposomes for the Targeted Drug Delivery of Oxaliplatin.
Autorzy :
Li Y; China Pharmaceutical University, Center for Research Development and Evaluation of Pharmaceutical Excipients and Generic Drugs, Nanjing 210009, People's Republic of China.
Xu P; China Pharmaceutical University, Center for Research Development and Evaluation of Pharmaceutical Excipients and Generic Drugs, Nanjing 210009, People's Republic of China.
He D; China Pharmaceutical University, Center for Research Development and Evaluation of Pharmaceutical Excipients and Generic Drugs, Nanjing 210009, People's Republic of China.
Xu B; School of Pharmacy, Nantong University, Nantong 226001, People's Republic of China.
Tu J; China Pharmaceutical University, Center for Research Development and Evaluation of Pharmaceutical Excipients and Generic Drugs, Nanjing 210009, People's Republic of China.
Shen Y; China Pharmaceutical University, Center for Research Development and Evaluation of Pharmaceutical Excipients and Generic Drugs, Nanjing 210009, People's Republic of China.
Pokaż więcej
Źródło :
International journal of nanomedicine [Int J Nanomedicine] 2020 Sep 11; Vol. 15, pp. 6721-6734. Date of Electronic Publication: 2020 Sep 11 (Print Publication: 2020).
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*administration & dosage
Drug Delivery Systems/*methods
Liposomes/*administration & dosage
Liposomes/*chemistry
Oxaliplatin/*administration & dosage
Animals ; Antineoplastic Agents/pharmacokinetics ; Cell Line, Tumor ; Drug Stability ; Humans ; Liposomes/therapeutic use ; Male ; Mice, Inbred BALB C ; Molecular Imaging ; Neoplasms/drug therapy ; Oxaliplatin/pharmacokinetics ; Particle Size ; Rabbits ; Temperature ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
MicroRNAs in cancer therapy: Their involvement in oxaliplatin sensitivity/resistance of cancer cells with a focus on colorectal cancer.
Autorzy :
Ashrafizadeh M; Department of Basic Science, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran.
Zarrabi A; Sabanci University Nanotechnology Research and Application Center (SUNUM), Tuzla 34956, Istanbul, Turkey; Center of Excellence for Functional Surfaces and Interfaces (EFSUN), Faculty of Engineering and Natural Sciences, Sabanci University, Tuzla, Istanbul 34956, Turkey.
Hushmandi K; Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
Hashemi F; DVM. Graduated, Young Researcher and Elite Club, Kazerun Branch, Islamic Azad University, Kazeroon, Iran.
Hashemi F; Student Research Committee, Department of Physiotherapy, Faculty of Rehabilitation, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Samarghandian S; Healthy Ageing Research Center, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Najafi M; Radiology and Nuclear Medicine Department, School of Paramedical Sciences, Kermanshah University of Medical Sciences, Kermanshah, Iran. Electronic address: .
Pokaż więcej
Źródło :
Life sciences [Life Sci] 2020 Sep 01; Vol. 256, pp. 117973. Date of Electronic Publication: 2020 Jun 20.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Colorectal Neoplasms/*drug therapy
Colorectal Neoplasms/*metabolism
Drug Resistance, Neoplasm/*drug effects
MicroRNAs/*metabolism
Oxaliplatin/*therapeutic use
Animals ; Antineoplastic Agents/pharmacology ; Clinical Trials as Topic/methods ; Colorectal Neoplasms/genetics ; Drug Resistance, Neoplasm/physiology ; Humans ; MicroRNAs/genetics ; Oxaliplatin/pharmacology
Czasopismo naukowe
Tytuł :
Impact of Perfusate Concentration on Hyperthermic Intraperitoneal Chemotherapy Efficacy and Toxicity in a Rodent Model.
Autorzy :
Liesenfeld LF; Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.
Hillebrecht HC; Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.
Klose J; Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.
Schmidt T; Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.
Schneider M; Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany. Electronic address: .
Pokaż więcej
Źródło :
The Journal of surgical research [J Surg Res] 2020 Sep; Vol. 253, pp. 262-271. Date of Electronic Publication: 2020 May 07.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Chemotherapy, Cancer, Regional Perfusion/*methods
Colorectal Neoplasms/*pathology
Hyperthermia, Induced/*methods
Oxaliplatin/*administration & dosage
Peritoneal Neoplasms/*therapy
Animals ; Cell Line, Tumor ; Chemotherapy, Adjuvant/adverse effects ; Chemotherapy, Adjuvant/methods ; Chemotherapy, Cancer, Regional Perfusion/adverse effects ; Colorectal Neoplasms/mortality ; Colorectal Neoplasms/therapy ; Cytoreduction Surgical Procedures ; Dose-Response Relationship, Drug ; Female ; Humans ; Hyperthermia, Induced/adverse effects ; Mice ; Oxaliplatin/toxicity ; Peritoneal Neoplasms/mortality ; Peritoneal Neoplasms/secondary ; Peritoneum/drug effects ; Peritoneum/pathology ; Treatment Failure ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Platinum-containing regimens for triple-negative metastatic breast cancer.
Autorzy :
Egger SJ; Cancer Research Division, Cancer Council NSW, Sydney, Australia.
Chan MMK; Department of Medical Oncology, Central Coast Cancer Centre, Gosford Hospital, Gosford, Australia.
Luo Q; Cancer Research Division, Cancer Council NSW, Sydney, Australia.
Wilcken N; Medical Oncology, Crown Princess Mary Cancer Centre, Westmead, Australia.; Sydney Medical School, The University of Sydney, Sydney, Australia.
Pokaż więcej
Źródło :
The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2020 Oct 21; Vol. 10. Cochrane AN: CD013750. Date of Electronic Publication: 2020 Oct 21.
Typ publikacji :
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Carboplatin/*therapeutic use
Cisplatin/*therapeutic use
Oxaliplatin/*therapeutic use
Triple Negative Breast Neoplasms/*drug therapy
Antineoplastic Agents/adverse effects ; Bias ; Carboplatin/adverse effects ; Cisplatin/adverse effects ; Female ; Genes, BRCA1 ; Genes, BRCA2 ; Humans ; Nausea/chemically induced ; Oxaliplatin/adverse effects ; Progression-Free Survival ; Randomized Controlled Trials as Topic ; Triple Negative Breast Neoplasms/genetics ; Triple Negative Breast Neoplasms/mortality ; Vomiting/chemically induced
Czasopismo naukowe
Tytuł :
A new prognostic and predictive tool for shared decision making in stage III colon cancer.
Autorzy :
Sobrero AF; Medical Oncology Unit 1, Ospedale Policlinico San Martino - IRCCS, Genoa, Italy. Electronic address: .
Puccini A; Medical Oncology Unit 1, Ospedale Policlinico San Martino - IRCCS, Genoa, Italy.
Shi Q; Department of Health Science Research, Mayo Clinic, Rochester, MN, USA.
Grothey A; West Cancer Center and Research Institute, OneOncology, Germantown, TN, USA.
Andrè T; GERCOR Group, Sorbonne Université and Department of Medical Oncology, Hôpital St Antoine, Paris, France.
Shields AF; Karmanos Cancer Institute, Detroit, MI, USA.
Souglakos I; Department of Medical Oncology, University Hospital of Heraklion, Faculty of Medicine University of Crete, Greece.
Yoshino T; National Cancer Center Hospital East, Japan.
Iveson T; University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Ceppi M; Unit of Clinical Epidemiology, Ospedale Policlinico San Martino - IRCCS, Genoa, Italy.
Bruzzi P; Unit of Clinical Epidemiology, Ospedale Policlinico San Martino - IRCCS, Genoa, Italy.
Pokaż więcej
Źródło :
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2020 Oct; Vol. 138, pp. 182-188. Date of Electronic Publication: 2020 Sep 03.
Typ publikacji :
Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Clinical Decision-Making*
Colectomy*/adverse effects
Colectomy*/mortality
Decision Making, Shared*
Decision Support Techniques*
Patient Participation*
Antimetabolites, Antineoplastic/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Colonic Neoplasms/*therapy
Oxaliplatin/*administration & dosage
Antimetabolites, Antineoplastic/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Chemotherapy, Adjuvant ; Colonic Neoplasms/mortality ; Colonic Neoplasms/pathology ; Databases, Factual ; Disease-Free Survival ; Humans ; Neoplasm Staging ; Oxaliplatin/adverse effects ; Predictive Value of Tests ; Randomized Controlled Trials as Topic ; Risk Assessment ; Risk Factors ; Time Factors
Czasopismo naukowe
Tytuł :
Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
Autorzy :
Sakai D; Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Suita, Japan. Electronic address: .
Taniguchi H; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Sugimoto N; Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan.
Tamura T; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
Nishina T; Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
Hara H; Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan.
Esaki T; Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Denda T; Division of Gastroenterology, Chiba Cancer Center, Chiba, Japan.
Sakamoto T; Department of Gastroetererological Oncology, Hyogo Cancer Center, Akashi, Japan.
Okuda H; Department of Medical Oncology, Keiyukai Sapporo Hospital, Sapporo, Japan.
Satoh T; Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Suita, Japan.
Tsushima T; Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Makiyama A; Department of Hematology/Oncology, Japan Community Healthcare Organization Kyushu Hospital, Fukuoka, Japan.
Tsuda T; Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.
Hosokawa A; Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Toyama, Japan.
Kuramochi H; Department of Chemotherapy, Tokyo Women's Medical University, Yachiyo Medical Center, Yachiyo, Japan.
Tokunaga S; Department of Medical Oncology, Osaka City General Hospital, Osaka, Japan.
Moriwaki T; Division of Gastroenterology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Yasui H; Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
Ishida H; Department of Gastroenterology, National Hospital Organization Mito Medical Center, Mito, Japan.
Tsuji A; Department of Clinical Oncology, Kagawa University Faculty of Medicine, Kagawa, Japan.
Otsu S; Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan.
Shimokawa H; Department of Medical Oncology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Japan.
Baba E; Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Japan.
Sato M; Department of Gastroenterology and Hepatology, Ryugasaki Saiseikai Hospital, Ryugasaki, Japan.
Matsumoto S; Department of Medical Oncology, Kyoto University Hospital, Kyoto, Japan.
Ozaki Y; Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan.
Shinozaki K; Division of Clinical Oncology, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Tamagawa H; Department of Surgery, Osaka General Medical Center, Osaka, Japan.
Goto M; Cancer Chemotherapy Center, Osaka Medical College, Osaka, Japan.
Kadowaki S; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Fujii H; Department of Clinical Oncology, Jichi Medical University Hospital, Tochigi, Japan.
Koh Y; Internal Medicine III, Wakayama Medical University, Wakayama, Japan.
Yamazaki K; Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Hironaka S; Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan.
Kishimoto J; Center for Clinical and Translational Research, Kyushu University Hospital, Japan.
Boku N; Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Hyodo I; Division of Gastroenterology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Muro K; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Pokaż więcej
Źródło :
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2020 Aug; Vol. 135, pp. 11-21. Date of Electronic Publication: 2020 Jun 08.
Typ publikacji :
Clinical Trial, Phase II; Comparative Study; Equivalence Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenocarcinoma/*drug therapy
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Biomarkers, Tumor/*genetics
Cetuximab/*administration & dosage
Colorectal Neoplasms/*drug therapy
Fluorouracil/*administration & dosage
Irinotecan/*administration & dosage
Oxaliplatin/*administration & dosage
Panitumumab/*administration & dosage
Proto-Oncogene Proteins p21(ras)/*genetics
Adenocarcinoma/genetics ; Adenocarcinoma/mortality ; Adenocarcinoma/pathology ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cetuximab/adverse effects ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/mortality ; Colorectal Neoplasms/pathology ; Drug Resistance, Neoplasm ; Female ; Fluorouracil/adverse effects ; Humans ; Irinotecan/adverse effects ; Male ; Middle Aged ; Mutation ; Oxaliplatin/adverse effects ; Panitumumab/adverse effects ; Progression-Free Survival ; Time Factors
Czasopismo naukowe
Tytuł :
TAS-118 plus oxaliplatin in advanced gastric cancer: is it worth it?
Autorzy :
Samalin E; Department of Medical Oncology, Montpellier Cancer Institute, Montpellier 34298, France; IGF, CNRS, INSERM, Montpellier University, Montpellier, France. Electronic address: .
Adenis A; Department of Medical Oncology, Montpellier Cancer Institute, Montpellier 34298, France; IRCM, INSERM, Montpellier University, Montpellier, France.
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Aug; Vol. 21 (8), pp. 1002-1003. Date of Electronic Publication: 2020 Jul 16.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Oxaliplatin*
Stomach Neoplasms*
Cisplatin ; Humans ; Leucovorin ; Tegafur
Czasopismo naukowe
Tytuł :
Optimize the dose of oxaliplatin for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by radical surgery and adjuvant chemotherapy.
Autorzy :
Chang H; Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Tao YL; Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Jiang W; Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.; Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
Chen C; Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Liu SL; Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Ye WJ; Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. .; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. .
Gao YH; Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. .; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. .
Pokaż więcej
Źródło :
BMC cancer [BMC Cancer] 2020 Jun 01; Vol. 20 (1), pp. 498. Date of Electronic Publication: 2020 Jun 01.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Drug-Related Side Effects and Adverse Reactions/*epidemiology
Neoplasm Recurrence, Local/*epidemiology
Oxaliplatin/*administration & dosage
Rectal Neoplasms/*therapy
Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Capecitabine/administration & dosage ; Capecitabine/adverse effects ; Chemoradiotherapy, Adjuvant/methods ; Chemotherapy, Adjuvant/adverse effects ; Chemotherapy, Adjuvant/methods ; Disease-Free Survival ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug-Related Side Effects and Adverse Reactions/etiology ; Drug-Related Side Effects and Adverse Reactions/prevention & control ; Female ; Follow-Up Studies ; Humans ; Incidence ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoadjuvant Therapy/methods ; Neoplasm Metastasis/prevention & control ; Neoplasm Recurrence, Local/prevention & control ; Neoplasm Staging ; Oxaliplatin/adverse effects ; Photons/therapeutic use ; Proctectomy ; Radiotherapy, Conformal/methods ; Rectal Neoplasms/pathology ; Rectum/drug effects ; Rectum/pathology ; Rectum/radiation effects ; Rectum/surgery ; Young Adult
Czasopismo naukowe
Tytuł :
Topical Delivery of Four Neuroprotective Ingredients by Ethosome-Gel: Synergistic Combination for Treatment of Oxaliplatin-Induced Peripheral Neuropathy.
Autorzy :
Lin HM; Beijing Research Institute of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, People's Republic of China.
Lin LF; Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, People's Republic of China.
Sun MY; Department of TCM Pharmaceutics, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, People's Republic of China.
Liu J; Department of TCM Pharmaceutics, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, People's Republic of China.
Wu Q; Department of TCM Pharmaceutics, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, People's Republic of China.
Pokaż więcej
Źródło :
International journal of nanomedicine [Int J Nanomedicine] 2020 May 07; Vol. 15, pp. 3251-3266. Date of Electronic Publication: 2020 May 07 (Print Publication: 2020).
Typ publikacji :
Journal Article
MeSH Terms :
Gels/*chemistry
Neuroprotective Agents/*therapeutic use
Oxaliplatin/*adverse effects
Peripheral Nervous System Diseases/*chemically induced
Peripheral Nervous System Diseases/*drug therapy
Acrolein/analogs & derivatives ; Acrolein/chemistry ; Administration, Topical ; Animals ; Behavior, Animal ; Drug Liberation ; Drug Synergism ; Ganglia, Spinal/cytology ; Liposomes ; Male ; Neurons/drug effects ; Neuroprotective Agents/administration & dosage ; Neuroprotective Agents/pharmacology ; Oxaliplatin/administration & dosage ; Particle Size ; Rats, Wistar ; Rheology ; Skin/metabolism ; Skin Absorption/drug effects
Czasopismo naukowe
Tytuł :
Curcumin β-D-glucuronide exhibits anti-tumor effects on oxaliplatin-resistant colon cancer with less toxicity in vivo.
Autorzy :
Ozawa-Umeta H; Therabiopharma Inc., Kanagawa, Japan.
Kishimoto A; Therabiopharma Inc., Kanagawa, Japan.
Imaizumi A; Therabiopharma Inc., Kanagawa, Japan.
Hashimoto T; Therabiopharma Inc., Kanagawa, Japan.
Asakura T; Radioisotope Research Facilities, Research Center for Medical Science, Jikei University School of Medicine, Tokyo, Japan.
Kakeya H; Department of System Chemotherapy and Molecular Sciences, Division of Bioinformatics and Chemical Genomics, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.
Kanai M; Department of Medical Oncology, Kyoto University Hospital, Kyoto, Japan.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2020 May; Vol. 111 (5), pp. 1785-1793. Date of Electronic Publication: 2020 Apr 07.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Colonic Neoplasms/*drug therapy
Curcumin/*analogs & derivatives
Drug Resistance, Neoplasm/*drug effects
Glucuronides/*therapeutic use
Oxaliplatin/*pharmacology
Animals ; Antineoplastic Agents/chemistry ; Antineoplastic Agents/pharmacokinetics ; Antineoplastic Agents/pharmacology ; Colonic Neoplasms/genetics ; Colonic Neoplasms/metabolism ; Curcumin/chemistry ; Curcumin/pharmacokinetics ; Curcumin/pharmacology ; Curcumin/therapeutic use ; Female ; Glucuronidase/metabolism ; Glucuronides/chemistry ; Glucuronides/pharmacokinetics ; Glucuronides/pharmacology ; HCT116 Cells ; Humans ; Mice ; Mice, Nude ; Mutation ; NF-kappa B/metabolism ; Oxaliplatin/therapeutic use ; Prodrugs ; Proto-Oncogene Proteins p21(ras)/genetics ; Signal Transduction/drug effects ; Tumor Suppressor Protein p53/genetics ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Bioinspired hyaluronic acid and polyarginine nanoparticles for DACHPt delivery.
Autorzy :
Matha K; Micro et Nanomédecines Translationnelles, MINT, UNIV Angers, UMR INSERM 1066, UMR CNRS 6021, Angers, France; CHU Angers, Département Pharmacie, 4 rue Larrey, 49933 Angers cedex 9, France.
Lollo G; University of Lyon, Université Claude Bernard Lyon 1, CNRS, LAGEPP UMR 5007, 43 Bd 11 Novembre 1918, 69622 Villeurbanne, France.
Taurino G; Department of Biomedical, Biotechnological, and Translational Sciences, University of Parma, 43100 Parma, Italy.
Respaud R; Centre d'Étude des Pathologies Respiratoires-CEPR, Institut National de la Santé et de la Recherche Médicale-INSERM, Unité Mixte de Recherche UMR 1100, Labex Mabimprove, 37000 Tours, France; Centre Hospitalier Régional Universitaire-CHRU de Tours, Hôpital Trousseau, Service de Pharmacie, 37170 Chambray-les-Tours, France.
Marigo I; Istituto Oncologico Veneto, IOV-IRCCS, 35128 Padova, Italy.
Shariati M; Ghent Research Group on Nanomedicines, Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Bussolati O; Department of Biomedical, Biotechnological, and Translational Sciences, University of Parma, 43100 Parma, Italy.
Vermeulen A; Laboratory of Medical Biochemistry and Clinical Analysis, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, B-9000 Ghent, Belgium.
Remaut K; Ghent Research Group on Nanomedicines, Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Benoit JP; Micro et Nanomédecines Translationnelles, MINT, UNIV Angers, UMR INSERM 1066, UMR CNRS 6021, Angers, France; CHU Angers, Département Pharmacie, 4 rue Larrey, 49933 Angers cedex 9, France. Electronic address: .
Pokaż więcej
Źródło :
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V [Eur J Pharm Biopharm] 2020 May; Vol. 150, pp. 1-13. Date of Electronic Publication: 2020 Feb 28.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Carriers*
Nanoparticles*
Antineoplastic Agents/*administration & dosage
Hyaluronic Acid/*chemistry
Oxaliplatin/*administration & dosage
Peptides/*chemistry
A549 Cells ; Animals ; Antineoplastic Agents/chemistry ; Antineoplastic Agents/pharmacokinetics ; Cell Survival/drug effects ; Colonic Neoplasms/drug therapy ; Colonic Neoplasms/pathology ; Drug Compounding ; Drug Stability ; Female ; HT29 Cells ; Humans ; Injections, Intravenous ; Lung Neoplasms/drug therapy ; Lung Neoplasms/pathology ; Mice, Inbred C57BL ; Models, Biological ; Oxaliplatin/chemistry ; Oxaliplatin/pharmacokinetics ; Tissue Distribution
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies